Article Figures & Data
Figures
- Figure 1.
Sustained Response to Secukinumab at Week 52
Missing values were imputed as nonresponse (nonresponder imputation) up to week 24. Observed data from week 28 to 52.
IV, intravenous; SC, subcutaneous.
*P < .0001 vs placebo (P values at week 24 adjusted for multiplicity of testing).
Reproduced with permission from P Mease, MD.
- Figure 2.
Resolution of Dactylitis and Enthesitis at Weeks 24 and 52
IV, intravenous; SC, subcutaneous.
*P < .0001 vs placebo.
Reproduced with permission from P Mease, MD.
Tools
Efficacy of Secukinumab Sustained over Time for Treatment of Active PsA
Permalink:
Table of contents
Cited By...
- No citing articles found.